David Cordani built Cigna over 17 years and now measures his success by how much people forget him
There is a category of success that few organisations know how to manufacture: the kind that becomes invisible. David Cordani, who took the helm of Cigna in 2009 when the company was billing around 18 billion dollars a year, steps down from the position of CEO on 1 July 2026 having taken that figure to 275 billion. He leaves the role with a definition of victory that is uncomfortable precisely because it is difficult to fake: he wants to be "something forgotten" because his successor, Brian Evanko, and his team are so effective that nobody needs to remember him.
That phrase deserves a cool-headed analysis, without automatic flattery. Not because Cordani does not believe it, but because the distance between saying it and having built it structurally is exactly where it is worth looking.
---
The acquisition that redefined the company, not just its size
The leap from 18 billion to 275 billion dollars in annual revenues was neither linear nor purely organic. The pivotal moment was 2018, with the acquisition of Express Scripts, one of the three major pharmacy benefit managers in the United States alongside CVS Caremark and OptumRx. That operation did not simply enlarge Cigna: it reconfigured it. It created the conditions for Evernorth — the health services, pharmacy and data analytics platform — to become the primary engine of growth, to the point where recent quarterly results show year-on-year growth of between 10% and 30%, almost all concentrated in that segment.
The strategic logic is the same one applied by UnitedHealth Group with Optum, or by CVS Health when it absorbed Aetna and subsequently acquired primary care assets. The sector's major players stopped competing solely as insurers and began building what might be called healthcare intermediation platforms: entities that control the flow of information, prescriptions, clinical data and employer relationships. Cigna arrived late to that reconfiguration compared to UnitedHealth, but the Express Scripts acquisition was forceful enough to prevent it from falling behind.
What makes Cordani's legacy analytically interesting is not the size that was reached, but the architecture that was left behind. Evernorth generates revenues at a massive scale, but it also represents a significant concentration of regulatory risk: the pharmacy benefit management business sits at the heart of legislative debates about drug pricing in the United States. Any reform that affects benefit managers — and there are active proposals to that effect — would land directly on the backbone of Cigna's model. That is not a neutral inheritance.
---
When leadership becomes more expensive than it appears
Cordani spoke in his interview with Fortune about how he understands leadership today: less hierarchical, more oriented towards accompaniment, with authenticity and the capacity to adapt. He also admitted his greatest regret: not having listened carefully enough in the early stages. "The impatience of a type-A orientation towards action gets in the way of truly understanding," he said.
That confession has a specific value that goes beyond public humility. Cordani has spent 17 years in the role and 25 in leadership positions within the organisation. That builds culture, but it also sediments patterns. When a long-tenured CEO describes in retrospect that he needed time to develop active listening, what he is describing without naming it is the period during which the organisation probably learned to adapt to his style rather than he to the signals of the system. That is not an accusation: it is a well-documented mechanic in high-performance organisations with highly stable leaders.
The structural question is not whether Cordani was a good CEO. The question is whether Cigna built, during those 17 years, the capacity to generate difficult decisions without him. And here the most revealing data point is not in the revenues: it is in the transition itself. Cordani is not leaving to pursue new external projects or to found something of his own. He is taking on the role of executive chairman of the board, which means he will continue to be an active institutional presence while Brian Evanko takes his first steps as CEO. That may be a necessary safety net, or it may be the signal that the system does not yet fully trust itself to operate without him nearby.
There is no definitive answer in the available data. But it is the kind of ambiguity that is worth sustaining without resolving it too quickly.
---
The pandemic as a test of governance, not just of character
One of the episodes that Cordani cited as his "leadership moment" occurred during the COVID-19 pandemic. From the executive committee of the sector association, he pushed for health plans to cover the costs of vaccination without a co-payment. When he secured that agreement in less than two hours with the Department of Health and the White House, he went further: he proposed that insurers eliminate the co-payment for all services related to COVID-19, not just vaccines. "If not now, when?", as he himself recounted. Cigna was the first major insurer to make that decision.
What makes this episode analytically valuable is not the altruistic gesture, but the way in which Cordani describes the internal process: "The board never said 'let's look at the business case and the impact on EPS'. We said that our mission guides this decision." That sentence describes a governance system where the CEO had sufficient political capital to bypass the financial analysis in a decision with a direct impact on revenues, and where the board backed him without friction.
That can be read as institutional maturity, and it probably is. But it also describes an organisation where the CEO's moral authority was high enough that the usual process of financial validation was suspended. That level of internal capital takes decades to accumulate and does not transfer automatically with the title. Brian Evanko will inherit the strategy and the revenues; he will not inherit that reserve of legitimacy in the same way. He will need to build his own, and probably under more difficult conditions: with greater regulatory scrutiny over the pharmaceutical sector, with an industry that is still processing the impact of the assassination of the CEO of UnitedHealthcare at the end of 2024, and with a political environment that is more hostile towards the major players in the healthcare system.
---
What artificial intelligence reveals about the next cycle
Cordani was deliberately measured about artificial intelligence. He used a phrase that has been circulating for years in corporate technology conversations — that we tend to overestimate the impact over two years and underestimate it over ten — but applied it with a concrete nuance: he does not believe that artificial intelligence is ready to make clinical decisions, but he does believe it is ready to organise and curate the information that supports them. And he added something that rarely appears in the enthusiastic speeches about automation in healthcare: that artificial intelligence amplifies cybersecurity risks in a significant way.
That warning has direct budgetary implications for the next CEO. Evernorth manages massive volumes of health data, prescriptions and pharmaceutical transactions. A cybersecurity incident at that scale would not merely be an operational problem: it would affect the trust of the employers who contract its services, it would trigger regulatory liabilities across multiple states, and it would generate a debate about whether the concentration of data in a few pharmacy benefit platforms represents a systemic risk to the healthcare system. Cordani's public stance on departure, which balances optimism about artificial intelligence with explicit concern about cybersecurity, is not coincidental: it is a way of framing where capital will flow in the coming years.
For Evanko's first quarterly cycles, analysts will be watching whether investments in security infrastructure are accelerated or whether the company prioritises the deployment of efficiency-oriented artificial intelligence. The two bets are not incompatible, but the sequence matters. An organisation that deploys artificial intelligence capabilities in benefit management before strengthening its defensive posture is making a risk decision that may not be visible in the financial statements until it is too late.
---
The system that endures is the one that can operate without the name that built it
Seventeen years is a long time to build an organisation, and also for that organisation to learn to function around a specific person. Not all organisations that grow to that scale under stable leadership do so with an equal distribution of real decision-making capacity. Some produce capable leaders at multiple levels; others produce executives who are excellent at managing the priorities of the CEO.
The case of Cigna is more complex than either caricature. The company grew, yes, but it did so largely through an acquisition that refounded its business model and that required years of integration under the direct supervision of the person who drove it. Evernorth exists as a platform because Cordani bet on that direction and had the political capital to sustain it. The transition now tests whether that bet was sufficiently institutionalised to survive independently, or whether it depends on someone with his specific weight continuing to be present in the room.
The fact that Cordani remains as executive chairman of the board does not invalidate the succession process, but it is relevant information. The best transfers of command do not require the predecessor to be available as a safety net during the first quarters. They require that the system has been designed so that such a net is unnecessary. If Cigna's transition proves as smooth as Cordani desires, the most eloquent signal will not be that nobody remembers him: it will be that Evanko makes difficult decisions without needing to consult upwards. That is what distinguishes a structural legacy from a personal one, and it is what the next eighteen months will begin to reveal with concrete data.
